Basiliximab
Common brands: Simulect, Prograf, Envarsus Xr, Tacrolimus, Cellcept
Top reporter: Novartis Pharmaceuticals Corporation
Interleukin-2 Receptor Blocking Antibody [EPC]Calcineurin Inhibitor Immunosuppressant [EPC]Corticosteroid [EPC]Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]Kinase Inhibitor [EPC]
11,495
Total Reports
5,585
Serious Reports
2,448
Death Reports
30
Reported Reactions
Death Report Ratio: High (21.30%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Basiliximab.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | OFF LABEL USE | 965 | |
| 2 | CYTOMEGALOVIRUS INFECTION | 904 | |
| 3 | DRUG INEFFECTIVE | 889 | |
| 4 | TRANSPLANT REJECTION | 851 | |
| 5 | KIDNEY TRANSPLANT REJECTION | 768 | |
| 6 | PYREXIA | 611 | |
| 7 | PRODUCT USE IN UNAPPROVED INDICATION | 536 | |
| 8 | BLOOD CREATININE INCREASED | 511 | |
| 9 | DIARRHOEA | 500 | |
| 10 | RENAL IMPAIRMENT | 460 | |
| 11 | ANAEMIA | 436 | |
| 12 | ACUTE KIDNEY INJURY | 421 | |
| 13 | SEPSIS | 419 | |
| 14 | MULTIPLE ORGAN DYSFUNCTION SYNDROME | 410 | |
| 15 | THROMBOTIC MICROANGIOPATHY | 396 | |
| 16 | PNEUMONIA | 393 | |
| 17 | POLYOMAVIRUS-ASSOCIATED NEPHROPATHY | 384 | |
| 18 | URINARY TRACT INFECTION | 375 | |
| 19 | LEUKOPENIA | 366 | |
| 20 | NEUTROPENIA | 356 | |
| 21 | COMPLICATIONS OF TRANSPLANTED KIDNEY | 348 | |
| 22 | TOXICITY TO VARIOUS AGENTS | 341 | |
| 23 | RESPIRATORY FAILURE | 329 | |
| 24 | THROMBOCYTOPENIA | 293 | |
| 25 | BK VIRUS INFECTION | 290 | |
| 26 | CYTOMEGALOVIRUS VIRAEMIA | 287 | |
| 27 | PANCYTOPENIA | 263 | |
| 28 | SEPTIC SHOCK | 263 | |
| 29 | RENAL TUBULAR NECROSIS | 261 | |
| 30 | POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER | 256 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.